INTRODUCTION
The patentability of human genes and stem cells has been heavily debated in the last decade by members of both the scientific and legal communities. While " [t] he fundamental policy of the patent system is to encourage the creation and disclosure of new, useful, and nonobvious advances in technology and design by granting the inventor the reward of exclusive right to practice the invention for a period of years," this reward of innovation is not without risk. 1 The patent system must be cautious of the legal monopoly patents provide, which has the potential to bring competition and further innovation to a halt. This balancing act is especially important in biological patenting, where patents have the potential to hinder the research, accessibility, and affordability of diagnostic tests and medical treatments.
On June 13, 2013, the United States Supreme Court, in Association for Molecular Pathology v. Myriad Genetics, Inc., issued a unanimous landmark decision that held that patents on human genes are invalid because "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated."
2 This holding invalidated Myriad Genetics' patents on the BRCA1 and BRCA2 genes, which are linked to an increased risk of breast and ovarian cancers. 3 In the weeks following the decision, other biotech companies began offering genetic testing for these genes, and the costs to patients for the preventive tests were significantly lowered. 4 The lower costs of these tests is particularly important considering recent American healthcare reform under the Patient Protection and Affordable Care Act ("ACA"), which places an emphasis on affordable and accessible preventative care. 5 While the Myriad decision made human genes ineligible for patents because they are a product of nature, the United States Supreme Court did not extend the holding of Myriad to the patenting of other isolated human biological materials, such as stem cells. 6 Because the Myriad decision did not close the door on the As the United States undergoes substantial health care reform and places an emphasis on affordable and preventive care, stem cell treatment therapies have the potential to provide a cost effective alternative to expensive lifelong treatments for chronic conditions. The purpose of this Note is to advocate that in light of Myriad, the invalidation of embryonic stem cell patents is necessary in order to further stem cell research and develop cost-saving treatments for chronic conditions. Part I of this Note provides a case study on Myriad by reviewing the science and reasoning behind the decision and explains how the invalidation of gene patents has altered the genetic testing landscape and helped to meet key provisions of the ACA. Part II provides a background on the science and current patenting landscape of stem cells. Part II also explains how stem cells are similar to genes and why they should be invalidated in light of Myriad. Part III analyzes what the United States stands to gain under the ACA from the invalidation of stem cell patents, including lowered costs for treatment of chronic conditions. Finally, Part IV proposes that Congress extend the Qualifying Therapeutic Discovery Project of the ACA as an alternative to stem cell patenting.
I. THE MYRIAD DECISION, GENETIC TESTING, AND THE AFFORDABLE CARE ACT: A CASE STUDY
The 1990s were a decade of rapid discovery and development in the genetics research and biotechnology fields. 9 In the midst of the Human Genome Project, large amounts of public and private funds were being invested in gene discovery and sequencing. 10 All of this research was being conducted in the wake of the United States Supreme Court case, Diamond v. Chakrabarty, 11 which allowed for the widespread patenting of biological organisms and genes. 12 At the American Society of Human Genetics Meeting in 1990, Doctor Mary-Claire King 10. Id. (noting that United States public expenditures on the Human Genome Project totaled more than $3 billion).
11. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (holding that plaintiff's genetically engineered bacterium was patentable because it was not naturally occurring and was "a product of human ingenuity").
12. Williams-Jones, supra note 9, at 125.
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announced that a gene associated with an increased risk in breast cancer, BRCA1, had been isolated. 13 In 1994, researchers at Utah-based biopharmaceutical and genomics company, Myriad Genetics, sequenced BRCA1 and "filed for U.S 'composition of matter' and 'methods-of-use' patents on the whole gene, as well as for a variety of deleterious mutations." 14 A year later, Myriad filed for a United States patent on the BRCA2 gene. 15 During the race to patent the various BRCA genes, the United States Patent and Trademark Office granted conflicting patents to various biotech companies in addition to the patents held by Myriad. 16 Myriad settled with the other companies and purchased all outstanding patents on the BRCA genes.
17

A. A Background on the Science: BRCA1 and BRCA2 Genetic Testing
After the completion of the Human Genome Project and the isolation of the BRCA1 and BRCA2 genes, Myriad's patents on the genes afforded the company with the sole right to develop and market a test to detect the presence of a BRCA mutation in women. 18 It took Myriad nearly two years' worth of research to develop a method of testing for the mutation and another three years of clinical trials before the test could be marketed to patients. 1. The Science Behind the BRCA Genes.-The BRCA1 and BRCA2 genes are human genes that produce tumor suppressor proteins and repair damaged DNA.
20
When these genes become mutated, they cannot carry out their designated repair functions. 21 Without repair, damaged cells become more likely to develop additional genetic alterations that can lead to cancer. 22 In the case of the BRCA genes, these inherited mutations lead to an increased risk of breast and ovarian cancers in women. 23 The harmful mutation can be inherited from either the mother or the father, which means that a child who has a parent that is a carrier of the BRCA mutation has a fifty percent chance of inheriting the mutated gene.
24
The risk of breast and ovarian cancer in women who have a mutation in either one of the BRCA genes is significant. 
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34
BRACAnalysis was considered a preventive screening and was therefore covered by many health insurance carriers. 35 If, however, Myriad Genetics did not have a contract with a particular health insurance company, patients were required to pay out of pocket. 36 With other medical procedures and preventive treatments, if an insurance company is not under contract with a particular pharmaceutical or biotech company, the insurance carrier typically has a contract with another provider that can provide the patient with a similar service. 37 In the case of BRCA gene mutation testing, Myriad was the only provider of the test.
38
Patients were left with no other options for the potentially lifesaving screening.
39
One of the main reasons that insurance companies were hesitant to enter into contracts with Myriad for the BRCA screening was the lack of scientific evidence demonstrating the effectiveness of the genetic tests. 40 Insurance companies were fearful the test would fail to detect a mutation or would give false positives. 41 The concern was that genetic testing would lead patients and their providers down "blind alleys," which would result in increased healthcare costs across the board. 42 High costs could come both from unnecessary treatments in cases where the test gave a false positive and from treatment for advanced conditions that failed to be detected by the screening. 43 Fear of increased health care costs was also the leading reason that government-funded insurance programs were hesitant to cover Myriad's BRACAnalysis. 44 As a way to discourage this preventive screening in Medicaid patients, many state Medicaid programs offered Myriad low reimbursement rates for BRACAnalysis. 45 The low reimbursement rates discouraged Myriad from entering into a contract with the state, leaving Medicaid patients without insurance coverage for the expensive test. 46 The ramifications of low coverage rates in the Medicaid population was significant because it left low income 34 58 Following her diagnosis, Girard decided to undergo the BRACAnalysis screening to determine if her cancer was genetic, thereby putting her at an increased risk for ovarian cancer. 59 The BRACAnalysis came back positive for a BRCA mutation, and Girard sought a second opinion to confirm the results of the test before undergoing a dramatic hysterectomy that would make her unable to have children. 60 However, because Myriad held the patent to the BRCA genes, no second opinion was available. 61 Similarly, Lisbeth Cerianai, a single mother who was diagnosed with bilateral breast cancer at the age of forty-two, also wanted to undergo the BRACAnalysis screening to determine her increased risk of ovarian cancer. 62 Cerianai was a Massachusetts Medicaid recipient and Medicaid would only cover the cost of the BRACAnalysis test if provided by a contracted provider.
63 Myriad was the only lab able to provide the test and refused to contract with Massachusetts Medicaid because the reimbursement rates were too low.
64
The cost of Myriad's BRACAnalysis was $3225. 65 Medicaid offered to pay Myriad only $1599, and Myriad refused a contract with the state. 66 If Ceriani wanted the test, she would have to pay the $3225 out of pocket. Myriad Genetics
Backed by women such as Lisbeth Ceriani and Genae Girard, as well as physicians and various medical researchers, the American Civil Liberties Union and the Public Patent Foundation filed suit alleging Myriad's patents on the BRCA genes should be invalidated as products of nature. 68 The suit made its way to the United States Supreme Court, ending Myriad's ongoing battle to defend its 57 intellectual property rights on the BRCA genes.
The Path to the United States Supreme
Court.-For women like Ceriani and Gerard, the Myriad decision provided hope that the preventive genetic testing market would expand to offer more testing options at a lower cost. After Myriad discovered the precise locations of the BRCA genes, it was not the only company initially to offer BRCA testing.
69 "The University of Pennsylvania's Genetic Diagnostic Laboratory [("GDL")] and others provided genetic testing services to women." 70 However, after Myriad learned that other companies were conducting genetic tests on the BRCA genes, it notified the companies that they were infringing on the Myriad patents. 71 As a result, GDL halted genetic tests on the BRCA genes. 72 Myriad also settled several patent infringement suits against other entities performing similar testing.
73
After Myriad became the sole company to provide BRCA testing, "medical patients, advocacy groups, and . . . doctors" filed suit to invalidate Myriad's patents under the Patent Act. 75 However, "phenomena of nature, although just discovered, mental processes, and abstract intellectual concepts are not patentable as they are basic tools of scientific and technological work." 76 This exception is necessary in scientific and biotechnological patenting because without it, future innovation based on these processes is inhibited. 77 It was on this foundation that the United States Supreme Court unanimously held that Myriad's patents were invalid as products of nature and thus not eligible for patent protection. 78 The Court found that isolating the BRCA1 and BRCA2 genes from the rest of the human genome through a separation technique did not make the genes patentable. 79 The Court held that "[t]he location and order of the nucleotides existed in nature before Myriad found them. Myriad [did not] create or alter the genetic structure of DNA. Instead, Myriad's principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes within the chromosomes."
80 While this isolation led to the discovery of a gene that revealed 
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81
It is important to note that the Court made clear that the holding of Myriad is limited to the patentability of human genes and does not apply to "method claims, patents on new applications of the knowledge about BRCA1 and BRCA2 genes, or the patentability of DNA in which the order of the naturally occurring nucleotides has been altered. The United States Supreme Court's invalidation of Myriad's patents on the BRCA genes opened up the genetic testing landscape for other providers to begin offering screenings for the BRCA mutations. 84 While the full results of the decision have yet to be seen, early indications of other companies beginning to offer the screening are promising and suggest that the price of genetic testing for predisposition to breast cancer could begin to decrease dramatically.
1. Political Landscape During the Myriad Decision.-On March 23, 2010, three years prior to the Myriad decision, President Barack Obama signed into law the Patient Protection and Affordable Care Act with the three main objectives of improving the quality of healthcare, lowering healthcare costs, and increasing access to healthcare. 85 With several provisions dedicated to these objectives,
[t]he Act will promote prevention, wellness, and the public health and provides unprecedented funding commitment to these areas. It directs the creation of a national prevention and health promotion strategy that incorporates the most effective and achievable methods to improve the health status of Americans and reduce the incidence of preventable illness and disability in the United States.
86
The decision of the United States Supreme Court to invalidate the patenting of human genes had repercussions far beyond the scientific and legal 81 89 The Marketplace is comprised of a series of state and federally run insurance exchanges that offer individual coverage for people who are unable to receive insurance through their employer. 90 Under the ACA, insurance plans purchased on the exchange must cover essential health benefits. 91 Outlined in Title I of the Act, "Quality and Affordable Health Care for All Americans," essential health benefits include the coverage of preventive and wellness services and place cost-sharing limits on these benefits for the patient.
92
The ACA includes preventive BRCA screenings for women in its definition of "preventive health services" by requiring that a health insurer offering a plan on The Marketplace provide coverage, without cost sharing requirements, on all services that the United States Preventive Service Task Force ("USPSTF") has given an "A" or "B" rating. 93 The USPSTF breaks down its recommendations into alphabetical classifications based on the importance of the recommendation in promoting health. 94 According to the Task Force, Grade A recommendations mean that there is a high certainty of substantial benefit and the USPSTF recommends the service. 95 Similarly, Grade B recommendations mean that there is moderate certainty that the benefit is moderate to substantial. 96 According to USPSTF, BRCA screening and counseling about the results of the screening are a Grade B recommendation and are therefore covered under the ACA with no patient cost 87 
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sharing.
97
"The USPSTF recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing." 98 Because insurers are now required to cover BRCA screening under the ACA, insurers will look to enter into the lowest contract price possible to provide the test.
99 This is important in light of another key feature of the ACA, the individual mandate. Under the individual mandate, all Americans are required to maintain minimum essential health coverage. 100 This requirement greatly "broaden[s] the health insurance risk pool to include healthy individuals."
101 Because everyone will be required to pay insurance premiums, the cost of covering the required minimum essential benefits will be passed on to the entire risk pool.
102 Therefore, it is beneficial not only to the insurance company, but also to the insured, for alternative BRCA screenings to be available on the market to drive down the cost. The Myriad decision has the potential to directly affect the cost of BRCA screenings because the invalidation of gene patents will allow companies other than Myriad to develop a test and potentially offer it at a reduced price. This cost savings has the potential to lower premiums for the insured.
In addition to cost savings on premiums, uninsured patients will benefit from the reassurance that they will not have to pay upwards of $3000 for the test. 103 Furthermore, patients facing the life altering decision of having a hysterectomy or mastectomy will have the option of seeking a second opinion. A second opinion could potentially save insurers from the costs of unnecessary surgery.
As well as private insurance companies being required to cover BRCA screenings for insurance policies purchased on the exchange, government-funded programs such as Medicare and Medicaid will also be required to cover the tests. 104 by citizen tax dollars, any decrease in cost of BRCA testing on the market could mean less expense for taxpayers. 105 While Myriad has refused to accept many government-funded programs' reimbursement rates, 106 the Myriad decision could foster the growth of competitors who would be more willing to offer testing to government insured patients at a reduced cost.
The Effect on Genetic
For many genetic conditions, insurance companies have refused to cover the cost of genetic tests but have been willing to pay for more expensive alternatives. For example, the major insurer Blue Cross Blue Shield will not cover the cost of a genetic test to screen for the inherited heart condition hypertrophic cardiomyopathy. 107 The genetic test is a one-time cost of $500. 108 However, as an alternative, Blue Cross Blue Shield will pay $2000 a year for the patient to receive an annual heart scan to look for the condition.
109
Despite insurance companies' refusal to cover them, genetic tests are increasing in popularity and are likely to continue to do so under a health reform that is focused on cost savings stemming from preventive care. 110 In the next ten years, spending on genetic tests is expected to increase over five times, from $5 billion to over $25 billion per year.
111 Just paying the upfront cost of a single genetic test can eliminate the costs associated with a lifetime of annual tests and treatments, costs that again will be passed on to all individuals in the risk pool; for those patients who are found not to have a genetic mutation, a one-time genetic screening can eliminate the cost of all future testing related to the genetic condition.
4 On February 7, 2014, the lawsuit against Gene by Gene was dropped and the parties entered into a settlement agreement. 125 Under the agreement, Gene by Gene will stop selling and marketing all BRCA tests in North America. 126 However, the company is allowed to sell the tests in all other countries worldwide. 127 The agreement lasts until February 6, 2016, when Myriad's BRCA patents expire.
128
While Myriad's case against Gene by Gene did not make it through the court system to determine whether or not Myriad's reign over BRCA testing stands, it is positive to see that other biotechnological companies are beginning to offer genetic screening for the BRCA mutation at reduced prices. This competition gives hope that the cost of the test and other similar genetic tests can be lowered. Reduced costs to insurance companies, patients, and taxpayers will help to achieve key provisions of the ACA regarding preventive care.
II. STEM CELLS: THE PATENTING LANDSCAPE
The opinion issued by the Court in Myriad was a narrow one and the Court did not extend its holding to patented method claims, applications of scientific knowledge, or cases of altered DNA. 129 Additionally, the opinion applied only to patents on isolated DNA and not other patented biological materials. 130 However, because of the scientific composition of the BRCA genes, the historical background behind the patenting of genes, and Myriad's monopoly of the genetic testing landscape, legal scholars have begun to question how the United States Supreme Court's view of Myriad's patents could be applied to other biotech patents in the near future, particularly stem cells. Stem cells are unique for three reasons: they are capable of long-term division and renewal; they are unspecialized, meaning they are not one distinct cellular type; and they can become many specialized cell types.
136
Human embryonic stem cells ("hES cells") are the cells that are found in three to five day embryos. 137 These cells give rise to the entire human body, from organs, to tissues, to sex cells. 138 For research purposes, embryonic stem cells are derived from eggs produced from in vitro fertilization and then donated for research.
139 Adult stem cells, found in many different organs and tissues in the body, have the primary role of repairing damaged tissue. 140 In contrast to hES cells, adult stem cells do not possess the same ability to give rise to a wide range of cells in the body; these stem cells are usually limited to producing cells of the same type. 156 meaning that WARF has ownership rights over all embryonic stem cells and the products created from them.
157
In exchange for funding, Geron required the "exclusive licensing of the technologies" developed by Dr. Thomson. 158 As a result, WARF entered into an agreement with Geron, giving Geron the exclusive right to turn the cells into a commercial treatment.
159 WARF later sued Geron to regain the commercial rights. 160 All rights were returned to WARF with the exception of the right to create treatments from nerve cells, heart tissue, and the pancreas. 161 Although Geron developed a stem cell spinal cord treatment, the company faced financial problems and halted all further stem cell research in 2011. 162 Geron still has the exclusive right to the nerve, heart, and pancreas treatments that could result in many lifesaving treatments for chronic conditions. 163 Geron's monopoly over these cells will decrease the competition among biotech firms who are unwilling to go through the difficult process to enter into licensing agreements with Geron. and academic institutions to begin research and development of possible stem cell therapies, the cost of licensing is high and has significantly driven up the cost of stem cell research.
167
As of 2007, WARF charged anywhere from $75,000 to $400,000 for a licensing agreement. 168 Additionally, companies entering into an agreement with WARF must also pay annual fees and royalties on any sales from potentially commercial products. 169 Unlike many other patent holders, WARF also charges a fee "per cell line, per investigator."
170 For small research programs and biotech firms, this rapidly increases the costs of conducting stem cell research. 171 As a result of its high licensing costs, WARF only has licensing agreements in place with approximately twenty-nine commercial companies, 172 including pharmaceutical giant Pfizer.
173
While WARF does not charge academic institutions to research stem cell lines, this does little to help to the furtherance of commercial medical products. Beginning in 2007, WARF implemented a new policy that allowed biopharmaceutical companies to sponsor embryonic stem cell research in academic institutions without a license. 174 While this allows these companies to conduct research without the high licensing fees they would pay in their own lab, the companies must still pay the fees as soon as they choose to remove the research from the university or as soon as they develop a commercial product.
175
In addition to hurdles created by WARF's high licensing fees, there are additional problems in the current stem cell patent landscape that make further research and development in the industry difficult. One such problem is the existence of a patent thicket or anti-commons.
176
"In a patent thicket, the existence of many overlapping patent claims can cause uncertainty about freedom to operate, impose multiple layers of transaction costs and stack royalty payments 167. Susan Decker, Gene Patent Case Fuels U.S. Court Test of Stem Cell Right, BLOOMBERG (Jan. 6, 2014, 12:01 AM), http://www.bloomberg.com/news/2014-01-06/gene-patent-case-fuels-us-court-test-of-stem-cell-right.html, archived at http://perma.cc/4FVE-4YC8; see also Miller, supra note 146, at 563 (discussing how academic and government researchers can use the stem cells for a small fee, and while they can publish their research or obtain patents on their discoveries, they must negotiate a licensing agreement with WARF in order to market a commercial product).
168 
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A LESSON LEARNED FROM MYRIAD 741 beyond levels that can be supported by the value of single innovations." 177 The problem with this thicket is that it creates too many hoops to jump though and slows the development of new technologies. 178 This thicket especially affects the small industry players who cannot afford the licensing costs to the various patents needed to effectively conduct research.
179
While WARF holds the two main patents to the stem cell lines and the methods of differentiation, different institutions have filed patents for other elements necessary for research. 180 These include factors such as the specific culture conditions, growth factors, proteins, and hormones that are required in order to differentiate the stem cells. 181 The patents on these items mean that there are few alternatives on the market.
182 Therefore, licenses must be obtained not only for the stem cells themselves but also for all of the various biological elements needed for research. 183 The various licenses greatly increase the cost of stem cell research and are likely to leave the field to large corporations willing to pay the high price. While some may argue that leaving the research and development of stem cell therapies to large pharmaceutical companies is best, it could lead to a situation similar to Myriad's BRACAnalysis where there are few treatment options on the market and consumers are faced with high out-of-pocket costs and little insurance coverage.
C. The Future of Stem Cell Patenting After the Myriad Decision
Since Myriad, legal scholars and members of the biotech industry have questioned how far Myriad's holding extends and whether or not it should cover the patenting of stem cells. 184 On July 2, 2013, the group Consumer Watchdog filed an appeal in the Federal Circuit asking for all patents on human embryonic stem cells to be invalidated as products of nature in light of Myriad. 185 
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A LESSON LEARNED FROM MYRIAD 743 different" from the product in its natural state. 198 Some of the factors weighing toward patentability include: the claim is something that appears to be natural, however it is different in structure and is not naturally occurring; the claim has elements that impose limits on the claim's scope so that others are not prevented from using the natural product; and the claim has elements that add to what is already well understood in the field of study.
199 Some of the factors weighing against patentability include: the claim is something that is a natural product not significantly different in structure from what is found in nature; the claims are general and cover all practical application of the natural product; and the claim states elements that must be taken by others in order to use the natural product. 200 In light of these factors issued by the USPTO, the Federal Circuit should seriously consider invalidating WARF's stem cell patents. The WARF patents are on stem cells that occur naturally in the human body, and while they may be modified to increase longevity, the fact that they can be used in the human body is an indication that they are not markedly different in structure than naturally occurring stem cells. Additionally, the WARF patents are so broad as to include all hESCs and their downstream products, essentially prohibiting anyone else in the field from using the cells in their natural state.
While it remains to be seen how the courts will come down on the patenting of stem cells as a product of nature, an invalidation of WARF's stem cell patents could have far reaching implications for the health care industry. As scientists inch closer to commercialized treatments using hES cells, a potential monopoly on the stem cell treatment industry is a real possibility. If the courts choose to invalidate the stem cell patents in light of Myriad, it could open up stem cell research and help to achieve key provisions of the ACA by developing treatment options that could lower the long term cost of chronic disease. such as diabetes and heart disease. 203 A major initiative of the ACA is the mandated coverage for those with preexisting conditions. 204 For many Americans with chronic conditions, their preexisting condition status prevented them from receiving health insurance prior to the ACA. As insurers will have to face the increased cost of insuring these individuals with ongoing chronic disease, stem cells offer the potential for a onetime treatment with an upfront cost as opposed to a lifetime of ongoing treatment. However, with licenses to the most promising stem cells being licensed to Geron Corporation, the invalidation of stem cell patents is an important step in opening up the research market to develop new therapies. 205 
III. HEALTH REFORM
A. The Cost of Ongoing Treatment of Chronic Disease
In the United States, nearly $0.75 of every health care dollar goes to treat patients with a chronic disease. 206 The amount of money spent on treating chronic illness in 2007 was "equivalent to paying 34 million salaries of $50,000 each." 207 "Chronic illness is a leading cause of premature death and disability in the United States with more than 133 million (45%) of Americans being afflicted with at least one chronic condition."
208 Seven out of every ten Americans will ultimately die of a chronic condition.
209
If the rate of chronic disorders in the United States continues to grow at the current rate, the cost will rise enormously by the year 2020. 210 For example, from 2010 to 2020 the cost of cancer is expected to increase 66%, from $125 billion to $207 billion; Alzheimer's 40%, from $172 billion to $241 billon; diabetes 58%, from $194 billion to $500 billion; and cardiovascular disease 73%, from $272 billion to $470 billion. 211 In 2010, the United States spent $2.6 trillion on health care costs alone. 212 That is nearly $8233 per person. 213 As the prevalence of chronic conditions continues to rise over the next decade, Americans will continue to spend progressively more on health care treatment costs; this cost will
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214
B. Insuring Citizens with Pre-Existing Conditions
One of the main pillars of the ACA is to provide insurance coverage for individuals who were previously denied on the basis of a pre-existing condition. 215 Pre-existing conditions are those medical conditions that an individual had before he enrolled in a health insurance plan. 216 Many preexisting conditions are chronic conditions such as asthma and heart disease.
217
The ACA states:
A group health plan and a health insurance issuer offering group or individual health insurance coverage may not establish rules for eligibility (including continued eligibility) of any individual to enroll under the terms of the plan. . . based on any of the following health status-related factors: health status, medical condition (including both physical and mental illness), claims experience, receipt of health care, medical history, genetic information, evidence of insurability (including conditions arising out of acts of domestic violence), disability, any other health status-related factor determined appropriate by the Secretary.
218
Where health insurers could previously deny coverage to adults with a preexisting chronic condition, the ACA mandates that these individuals be covered. The ACA pre-existing condition clause went into effect on January 1, 2014.
219
At this point, the rest of the ACA was already in place, including the individual mandate. 220 Because all Americans are required to have health insurance under the individual mandate, the cost of the chronic illness for those with a pre-existing condition is now being paid for by spreading the "cost of their illnesses . . . among a larger population of sick and healthy people." 221 This cost must be spread among the entire population because under the "community rating" provision of the ACA, "the health insurance company [ Enacted in 2010, Congress directed the program at small biotechnology firms (less than 250 employees) who had difficulties receiving funding from other sources. 269 The credit covered up to fifty percent of a biotech firm's qualified investment, up to $5 million. In 2010, the TPD resulted in almost 3000 biotech companies receiving a total $1 billion dollars. 270 In the state of Indiana alone, the federal government awarded thirty-five small biotech companies a tax credit or grant under the Qualifying Therapeutic Discovery Project. 271 Indiana companies received a total of $10,293,530.56 through the life of the program. 272 At least three of the Indiana projects awarded grant money were directly involved in stem cell research. 273 Congress did not renew the TPD after 2010. However, since 2010 a group of legislators has been trying to garner support for the renewal of the project. 274 If the holding in Myriad is any indication, the patents on stem cells and their methods of derivation could be invalidated in the near future. This could eliminate the incentive of WARF and those with WARF licensing agreements to continue further research and development for fear that their findings will not be patent eligible. However, the TPD could provide some relief from this and allow small biotech firms to fill the stem cell research gap, leading to potentially groundbreaking discoveries to cure chronic disease.
The TPD, as part of the ACA, has the potential to take the place of some of the rewards provided by the patent system in an effort to help increase research
